Home » Drug Information » FDA-Approved Drugs » 1998
Medical Areas: Cardiology/Vascular Diseases
View By: Year Company Therapeutic Areas Drug Names
Drug Information
The following information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Forest Laboratories
Approval Status: Approved February 1998
Treatment Area: chronic stable angina
Tiazac has been approved for use in the treatment of chronic
stable angina. Tiazac was previously approved for the treatment of
hypertension.
Tiazac has been shown to significantly reduce both angina attack
rates and nitroglycerin consumption. Tiazac's central effects
and peripheral vasodilating action balanced oxygen supply and
demand producing significantly greater increases in total duration
of exercise compared to placebo. Additionally, Tiazac effectively
reduced blood pressure of hypertensive patients over a 24-hour
dosing interval.
Side Effects: The side-effect profile is comparable to placebo,
even when dosed up to 360 mg.
Tiazac (diltiazem HCl) is a once-daily calcium channel
blocker.
